Cargando…
Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials
Leukemia is a group of malignant disorders which affect the blood and blood-forming tissues in the bone marrow, lymphatic system, and spleen. Many types of leukemia exist; thus, their diagnosis and treatment are somewhat complicated. The use of conventional strategies for treatment such as chemother...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696888/ http://dx.doi.org/10.1186/s40001-023-01539-z |
_version_ | 1785154668313182208 |
---|---|
author | Salama, Maha M. Aborehab, Nora M. El Mahdy, Nihal M. Zayed, Ahmed Ezzat, Shahira M. |
author_facet | Salama, Maha M. Aborehab, Nora M. El Mahdy, Nihal M. Zayed, Ahmed Ezzat, Shahira M. |
author_sort | Salama, Maha M. |
collection | PubMed |
description | Leukemia is a group of malignant disorders which affect the blood and blood-forming tissues in the bone marrow, lymphatic system, and spleen. Many types of leukemia exist; thus, their diagnosis and treatment are somewhat complicated. The use of conventional strategies for treatment such as chemotherapy and radiotherapy may develop many side effects and toxicity. Hence, modern research is concerned with the development of specific nano-formulations for targeted delivery of anti-leukemic drugs avoiding toxic effects on normal cells. Nanostructures can be applied not only in treatment but also in diagnosis. In this article, types of leukemia, its causes, diagnosis as well as conventional treatment of leukemia shall be reviewed. Then, the use of nanoparticles in diagnosis of leukemia and synthesis of nanocarriers for efficient delivery of anti-leukemia drugs being investigated in in vivo and clinical studies. Therefore, it may contribute to the discovery of novel and emerging nanoparticles for targeted treatment of leukemia with less side effects and toxicities. |
format | Online Article Text |
id | pubmed-10696888 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106968882023-12-06 Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials Salama, Maha M. Aborehab, Nora M. El Mahdy, Nihal M. Zayed, Ahmed Ezzat, Shahira M. Eur J Med Res Review Leukemia is a group of malignant disorders which affect the blood and blood-forming tissues in the bone marrow, lymphatic system, and spleen. Many types of leukemia exist; thus, their diagnosis and treatment are somewhat complicated. The use of conventional strategies for treatment such as chemotherapy and radiotherapy may develop many side effects and toxicity. Hence, modern research is concerned with the development of specific nano-formulations for targeted delivery of anti-leukemic drugs avoiding toxic effects on normal cells. Nanostructures can be applied not only in treatment but also in diagnosis. In this article, types of leukemia, its causes, diagnosis as well as conventional treatment of leukemia shall be reviewed. Then, the use of nanoparticles in diagnosis of leukemia and synthesis of nanocarriers for efficient delivery of anti-leukemia drugs being investigated in in vivo and clinical studies. Therefore, it may contribute to the discovery of novel and emerging nanoparticles for targeted treatment of leukemia with less side effects and toxicities. BioMed Central 2023-12-05 /pmc/articles/PMC10696888/ http://dx.doi.org/10.1186/s40001-023-01539-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Salama, Maha M. Aborehab, Nora M. El Mahdy, Nihal M. Zayed, Ahmed Ezzat, Shahira M. Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials |
title | Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials |
title_full | Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials |
title_fullStr | Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials |
title_full_unstemmed | Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials |
title_short | Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials |
title_sort | nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696888/ http://dx.doi.org/10.1186/s40001-023-01539-z |
work_keys_str_mv | AT salamamaham nanotechnologyinleukemiadiagnosisefficienttargeteddrugdeliveryandclinicaltrials AT aborehabnoram nanotechnologyinleukemiadiagnosisefficienttargeteddrugdeliveryandclinicaltrials AT elmahdynihalm nanotechnologyinleukemiadiagnosisefficienttargeteddrugdeliveryandclinicaltrials AT zayedahmed nanotechnologyinleukemiadiagnosisefficienttargeteddrugdeliveryandclinicaltrials AT ezzatshahiram nanotechnologyinleukemiadiagnosisefficienttargeteddrugdeliveryandclinicaltrials |